New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

DUPIXENT (dupilumab) injection

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

DUPIXENT is an interleukin-4 receptor alpha antagonist indicated:

  • Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with
    moderate-to-severe AD.
  • Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.
  • Chronic Rhinosinusitis with Nasal Polyposis as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
  • Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

Brand Name: DUPIXENT (dupilumab) injection, for subcutaneous use Initial U.S. Approval: 2017
API: dupilumab
Dosage Forms & Strengths:
Single-Dose Pre-Filled Syringe with Needle Shield :
• Injection: 300 mg/2 mL
• Injection: 200 mg/1.14 mL
Single-Dose Pre-Filled Pen:
• Injection: 300 mg/2 mL
• Injection: 200 mg/1.14 mL
Manufactured By: Regeneron
Prescribing Information URL: Click Here


Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). It has been shown to be effective at treating aspirin-exacerbated respiratory disease (AERD), a typically difficult to treat condition where aspirin intolerant patients have both CRSwNP and asthma.

In May 2022, the indication for dupilumab was updated to include the treatment of eosinophilic esophagitis in people aged twelve years of age and older weighing at least 40 kilograms (88 lb).

In September 2022, the indication for dupilumab was updated to include the treatment of adults with prurigo nodularis (PN).

In March 2023, the EMA approved dupilumab for the treatment of severe atopic dermatitis in children aged six months to five years who are candidates for systemic therapy.

South Delhi Pharma Can Supply dupilumab In India On Request –

dupilumab, sold under the brand name DUPIXENT®, is manufactured by Regeneron. It has been approved by the FDA. For pricing information on DUPIXENT® in India, please contact via phone or WhatsApp at +91-9891296838 or email at DUPIXENT® is supplied in form: For injection. It can be made available in various cities across India, including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim.

Related Products